Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK2 V617F JAK2 Q959H JAK2 L983F |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F, L983F, and Q959H was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 | |
JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | sensitive | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915). | 39091915 | |
JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | sensitive | Lestaurtinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915). | 39091915 | |
JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915). | 39091915 | |
JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915). | 39091915 |